Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS
Trial details
- Registry ID
- NCT03799718
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MSNCT03799718 | Brainstorm-Cell Therapeutics | Phase 2 | Completed | 2021-03-11Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |